Description: This MAb recognizes the peptide core of gastric mucin M1 (recently identified as Mucin 5AC). Its epitope is located in the N-terminal cysteine rich part of the peptide core of MUC5AC, which is heavily glycosylated. Its epitope is destroyed by beta-mercaptoethanol but not by periodate treatment. MAb 2-11M1 reacts with the protein backbone exclusively; it only reacts with fully deglycosylated MUC5AC. Therefore, the material under test should also be fully deglycosylated. This can be achieved with standard periodate oxidation method. The success of the deglycosylation can be checked with routine PAS (Periodic Acid Shiff) staining. After deglycosylation, the preparation should no longer be stainable with PAS reagent. Only then 2-11M1 will react should MUC5AC be present. This mucin is present in primary ovarian mucinous cancer but usually absent in colorectal adenocarcinoma, thus showing an expression pattern opposite to MUC2. Together with a panel of antibodies, Anti-MUC5AC may be useful for differential identification of primary mucinous ovarian tumors from colon adenocarcinoma metastatic to the ovary. MUC5AC antibodies may also be useful for identification of intestinal metaplasia as well as in the identification of pancreatic carcinoma and pre-cancerous changes vs. normal pancreas. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
Product origin: Animal - Mus musculus (mouse), Bos taurus (bovine)
Conjugate: CF740
Concentration: 0.1 mg/mL
Storage buffer: PBS, 0.1% rBSA, 0.05% azide
Clone: 2-12M1
Immunogen: M1 mucin preparation from the fluid of an ovarian mucinous cyst belonging to an O Le(a-b) patient
Antibody Reactivity: Gastric Mucin/MUC5AC
References: Note: References for this clone sold by other suppliers may be listed for expected applications.
- Int J Cancer (1998) 75: 767-773. (RIA)
- Arch Ophthamol (2007) 125 (10): 1337-1344 (IF, FFPE)
- FEBS J (2008) 275: 481-489. (WB, epitope mapping)
Entrez Gene ID: 4586
Expected AB Applications: RIA (published for clone)/IHC (FFPE) (published for clone)/WB (published for clone)
Z-Antibody Applications: IHC, FFPE (published)/RIA (published)/WB (published)
Antibody Application Notes: Flow cytometry: 0.5-1 ug/million cells; Immunofluorescence: 1-2 ug/mL; Optimal dilution for a specific application should be determined./Higher concentration may be required for direct detection using primary antibody conjugates than for indirect detection with secondary antibody
Deutsch
English
